Preclinical services support the early stages of drug development,where therapies are evaluated for safety,biological activity,and potential efficacy before entering human trials.
\nAs an early phase CRO,CellCarta provides these services,including biomarker discovery,tissue analysis,genomic profiling,and immune monitoring,to better understand how a therapy behaves in biological systems. High-quality preclinical data is critical for making informed decisions,refining therapeutic strategies,and building a strong foundation for regulatory submissions. Without this stage,programs risk entering the clinic without the evidence needed to succeed.
"},{"faq_question":"How does a multi-omic approach improve preclinical drug development outcomes?","faq_answer":"A multi-omic approach integrates data from genomics,proteomics,and other biomarker platforms to provide a more complete view of disease biology and treatment response. Instead of relying on a single data type,researchers can uncover deeper insights into mechanisms of action,identify more robust biomarkers,and reduce the risk of missed signals. This leads to better target validation,more precise patient stratification strategies,and stronger translational relevance as programs move toward the clinic.
\nWorking with an early phase CRO that offers integrated multi-omic capabilities helps ensure these insights translate into stronger preclinical development decisions.
"},{"faq_question":"What is the advantage of working with an integrated CRO partner for preclinical research? ","faq_answer":"Working with an integrated early phase CRO partner streamlines preclinical development by reducing fragmentation across vendors,platforms,and data outputs. Instead of coordinating multiple providers,programs gain access to a unified team that aligns on study design,assay selection,and data generation from the start.
\nThis improves consistency,reduces operational delays,and ensures data is generated in formats that support downstream regulatory requirements. An integrated approach also enables closer scientific collaboration,helping teams adapt quickly as new insights emerge throughout the program.
"},{"faq_question":"What types of biomarker assays does CellCarta offer for preclinical programs? ","faq_answer":"CellCarta offers a broad range of biomarker assays spanning multiple analytical platforms to support preclinical programs. Our early phase CRO capabilities include genomic technologies such as RNA-seq and CITE-seq,proteomic platforms such as Olink,and tissue-based analyses,including immunohistochemistry (IHC). Additional capabilities include flow cytometry,ELISpot,cytokine profiling,and targeted mass spectrometry for protein and stability analysis.
\nThis multi-omic toolkit allows for comprehensive characterization of biological responses across tissues,blood,and other sample types.
"},{"faq_question":"How does CellCarta support the transition from preclinical research to IND-enabling studies?","faq_answer":"CellCarta supports the transition to IND-enabling studies by generating high-quality,reproducible data that aligns with regulatory expectations. Teams work closely with our scientists to define biomarker strategies early,select appropriate platforms,and ensure assays are designed for translational relevance.
\nBecause services are integrated across disciplines and global labs,data is consistent and scalable as programs progress. This continuity helps bridge the gap between discovery and clinical development,enabling smoother progression into first-in-human trials and regulatory submissions.
"}]}#-supreme-cellcarta-featured-resources-8-168{cards-data:[{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"},{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar-2.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"},{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar-3.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"}]}#-supreme-cellcarta-how-it-works-12-168{steps-data:[{"step_label":"Step 01","title":"Biomarker Discovery ","description":"Discover new biomarkers with multi-omic assays. "},{"step_label":"Step 02","title":"Tissue Analysis","description":"Analyze expression and morphology via IHC."},{"step_label":"Step 03","title":"Genomic Expansion","description":"Expand preclinical datasets with genomic analysis. "},{"step_label":"Step 04","title":"Serum Cytokine Profiling","description":"Evaluate compound activity in blood. "},{"step_label":"Step 05","title":"Immune Response Monitoring","description":"Track responses with flow cytometry and ELISpot."},{"step_label":"Step 06","title":"Characterize Stability","description":"Assess stability of therapeutics via MS."}]}#-supreme-cellcarta-overview-4-168{stats-data:[{"number":"80% ","label":"Multimodal projects "},{"number":"200+","label":"Citations last year"},{"number":">40%","label":"MSc,PhD,MD scientists"}]}#-supreme-cellcarta-service-blocks-14-168{blocks-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Clinical-Trial-block-814.jpg","image_alt":"","title":"Clinical Trial Services","description":"Generate reliable,regulatory-ready data with harmonized global execution. ","button_text":"Explore Clinical Solutions","button_url":"/clinical-trial-services/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/08/CellCarta_-47-2-1-crop-to-models-scaled.jpg","image_alt":"","title":"Companion diagnostics (CDx) ","description":"From prototype assay to IVD CDx — development,validation,and submission support. ","button_text":"Explore CDx Solutions","button_url":"/clinical-trial-services/cdx-development/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/08/CellCarta-884-scaled.jpg","image_alt":"","title":"Regulatory Services ","description":"Navigate global regulatory requirements with expert guidance and submission support. ","button_text":"Explore regulatory solutions","button_url":"/clinical-trial-services/regulatory-services/","button_target":"_self"}]}